Literature DB >> 18838506

Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.

J Matthew Hutzler1, Larissa M Balogh, Michael Zientek, Vikas Kumar, Timothy S Tracy.   

Abstract

In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates. Although the inactivation of P450 2C9 by tienilic acid when (S)-flurbiprofen and diclofenac were used as substrates was similar (efficiency of approximately 9 ml/min/micromol), the inactivation kinetics were characterized by a sigmoidal profile. (+/-)-Suprofen inactivation of (S)-flurbiprofen and diclofenac hydroxylation was also described by a sigmoidal profile, although inactivation was markedly less efficient (approximately 1 ml/min/micromol). In contrast, inactivation of P450 2C9-mediated (S)-warfarin 7-hydroxylation by tienilic acid and (+/-)-suprofen was best fit to a hyperbolic equation, where inactivation efficiency was moderately higher (10 ml/min/micromol) and approximately 3-fold higher (3 ml/min/micromol), respectively, relative to that of the other probe substrates, which argues for careful consideration of reporter substrate when mechanism-based inactivation of P450 2C9 is assessed in vitro. Further investigations into the increased inactivation seen with tienilic acid relative to that with (+/-)-suprofen revealed that tienilic acid is a higher affinity substrate with a spectral binding affinity constant (K(s)) of 2 microM and an in vitro half-life of 5 min compared with a K(s) of 21 microM and a 50 min in vitro half-life for (+/-)-suprofen. Lastly, a close analog of tienilic acid with the carboxylate functionality replaced by an oxirane ring was devoid of inactivation properties, which suggests that an ionic binding interaction with a positively charged residue in the P450 2C9 active site is critical for recognition and mechanism-based inactivation by these close structural analogs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838506      PMCID: PMC2610245          DOI: 10.1124/dmd.108.023358

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

1.  CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.

Authors:  Vikas Kumar; Jan L Wahlstrom; Dan A Rock; Chad J Warren; Lee A Gorman; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2006-09-08       Impact factor: 3.922

Review 2.  Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.

Authors:  K Venkatakrishnan; R S Obach; A Rostami-Hodjegan
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

3.  A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.

Authors:  Chuang Lu; Gerald T Miwa; Shimoga R Prakash; Liang-Shang Gan; Suresh K Balani
Journal:  Drug Metab Dispos       Date:  2006-10-04       Impact factor: 3.922

4.  Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.

Authors:  G M Giancarlo; K Venkatakrishnan; B W Granda; L L von Moltke; D J Greenblatt
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

5.  Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

Authors:  Hayley S Brown; Aleksandra Galetin; David Hallifax; J Brian Houston
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Time-dependent CYP inhibition.

Authors:  Robert J Riley; Ken Grime; Richard Weaver
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-02       Impact factor: 4.481

7.  Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.

Authors:  R Scott Obach; Robert L Walsky; Karthik Venkatakrishnan
Journal:  Drug Metab Dispos       Date:  2006-11-08       Impact factor: 3.922

8.  Inhibition of CYP2B4 by the mechanism-based inhibitor 2-ethynylnaphthalene: inhibitory potential of 2EN is dependent on the size of the substrate.

Authors:  Dongmei Cheng; James R Reed; Danni Harris; Wayne L Backes
Journal:  Arch Biochem Biophys       Date:  2007-04-09       Impact factor: 4.013

9.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

10.  Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Drug Metab Dispos       Date:  2007-04-19       Impact factor: 3.922

View more
  8 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Authors:  Darcy R Flora; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2011-12-28       Impact factor: 3.922

3.  Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.

Authors:  Yakov M Koen; Diganta Sarma; Todd D Williams; Nadezhda A Galeva; R Scott Obach; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

4.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

5.  Conformational turn triggers regio-selectivity in the bioactivation of thiophene-contained compounds mediated by cytochrome P450.

Authors:  Chun-Zhi Ai; Yong Liu; Du-Chu Chen; Yasmeen Saeed; Yi-Zhou Jiang
Journal:  J Biol Inorg Chem       Date:  2019-09-10       Impact factor: 3.358

Review 6.  The endoplasmic reticulum participated in drug metabolic toxicity.

Authors:  Qingcai Huang; Youwen Chen; Zhengjia Zhang; Zeyu Xue; Zhenglai Hua; Xinyi Luo; Yang Li; Cheng Lu; Aiping Lu; Yuanyan Liu
Journal:  Cell Biol Toxicol       Date:  2022-01-18       Impact factor: 6.691

7.  In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.

Authors:  Tae Yeon Kong; Soon-Sang Kwon; Jae Chul Cheong; Hee Seung Kim; Jin Young Kim; Hye Suk Lee
Journal:  Molecules       Date:  2018-04-16       Impact factor: 4.411

Review 8.  Monooxygenase- and Dioxygenase-Catalyzed Oxidative Dearomatization of Thiophenes by Sulfoxidation, cis-Dihydroxylation and Epoxidation.

Authors:  Derek R Boyd; Narain D Sharma; Paul J Stevenson; Patrick Hoering; Christopher C R Allen; Patrick M Dansette
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.